Your browser is no longer supported. Please, upgrade your browser.
Revance Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.60 Insider Own1.80% Shs Outstand66.55M Perf Week-12.32%
Market Cap1.74B Forward P/E- EPS next Y-4.06 Insider Trans-12.07% Shs Float61.54M Perf Month-9.37%
Income-249.10M PEG- EPS next Q-1.24 Inst Own84.60% Short Float6.38% Perf Quarter6.19%
Sales4.30M P/S403.71 EPS this Y6.90% Inst Trans5.18% Short Ratio8.35 Perf Half Y2.45%
Book/sh6.16 P/B4.21 EPS next Y14.30% ROA-44.90% Target Price36.80 Perf Year-3.72%
Cash/sh6.50 P/C3.98 EPS next 5Y11.60% ROE-85.70% 52W Range11.78 - 34.62 Perf YTD-8.57%
Dividend- P/FCF- EPS past 5Y-2.50% ROI-72.90% 52W High-24.32% Beta1.26
Dividend %- Quick Ratio7.00 Sales past 5Y1.50% Gross Margin74.20% 52W Low122.41% ATR1.32
Employees193 Current Ratio7.10 Sales Q/Q8237.00% Oper. Margin- RSI (14)39.43 Volatility5.49% 4.74%
OptionableYes Debt/Eq0.48 EPS Q/Q-40.40% Profit Margin- Rel Volume0.84 Prev Close25.91
ShortableYes LT Debt/Eq0.48 EarningsFeb 22 AMC Payout- Avg Volume470.28K Price26.20
Recom1.80 SMA20-6.19% SMA50-6.00% SMA2001.99% Volume389,227 Change1.12%
Oct-15-20Reiterated Needham Buy $36 → $42
Aug-11-20Resumed Mizuho Buy $32
Mar-23-20Downgrade Goldman Buy → Neutral $32 → $15
Dec-02-19Initiated Goldman Buy
Oct-30-19Upgrade Wells Fargo Market Perform → Outperform $20
Jun-11-19Initiated Barclays Overweight $28
Feb-15-19Initiated Wells Fargo Market Perform
Feb-14-19Initiated H.C. Wainwright Buy $25
Jan-29-19Initiated Stifel Buy $50
Nov-16-18Upgrade Guggenheim Neutral → Buy
Sep-17-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Apr-20-18Reiterated Mizuho Buy $54 → $48
Mar-27-18Initiated Needham Buy $42
Mar-05-18Initiated Goldman Buy $60
Jan-09-18Downgrade Guggenheim Buy → Neutral
Dec-06-17Reiterated Mizuho Buy $37 → $54
Dec-06-17Initiated Guggenheim Buy $42
Nov-27-17Initiated Barclays Overweight $31
Nov-17-17Initiated Mizuho Buy $37
Aug-22-17Initiated JMP Securities Mkt Outperform $34
Feb-24-21 04:05PM  
Feb-23-21 04:05PM  
Feb-22-21 05:25PM  
Feb-19-21 10:40AM  
Feb-12-21 08:00AM  
Jan-25-21 08:00AM  
Jan-22-21 08:00AM  
Jan-19-21 04:05PM  
Jan-11-21 07:45AM  
Jan-07-21 04:05PM  
Dec-23-20 01:30PM  
Dec-22-20 08:00AM  
Dec-21-20 04:05PM  
Dec-17-20 08:05AM  
Dec-16-20 08:30AM  
Dec-14-20 10:47AM  
Nov-27-20 01:31PM  
Nov-25-20 08:30AM  
Nov-24-20 04:05PM  
Nov-20-20 04:05PM  
Nov-11-20 08:08AM  
Nov-10-20 04:05PM  
Nov-09-20 05:16PM  
Nov-06-20 09:00AM  
Nov-03-20 04:05PM  
Nov-02-20 04:05PM  
Oct-23-20 04:05PM  
Oct-14-20 08:00AM  
Oct-06-20 08:00AM  
Oct-05-20 10:15AM  
Sep-23-20 04:05PM  
Sep-08-20 04:05PM  
Sep-02-20 08:00AM  
Aug-28-20 11:29AM  
Aug-25-20 08:00AM  
Aug-11-20 08:30AM  
Aug-06-20 04:05PM  
Jul-30-20 04:05PM  
Jul-24-20 09:46AM  
Jul-23-20 06:20PM  
Jul-05-20 03:28PM  
Jun-30-20 04:05PM  
Jun-26-20 09:57AM  
Jun-18-20 12:27PM  
Jun-09-20 08:10PM  
Jun-04-20 04:05PM  
Jun-02-20 04:05PM  
Jun-01-20 08:30AM  
May-20-20 08:12AM  
May-19-20 08:01AM  
May-09-20 10:01PM  
May-07-20 04:05PM  
May-01-20 08:30AM  
Apr-30-20 04:05PM  
Apr-27-20 09:16AM  
Apr-21-20 08:05AM  
Apr-09-20 08:55AM  
Apr-07-20 04:05PM  
Mar-26-20 04:05PM  
Mar-25-20 08:36AM  
Mar-07-20 12:26AM  
Mar-03-20 04:05PM  
Feb-27-20 01:08PM  
Feb-25-20 04:05PM  
Feb-24-20 04:05PM  
Feb-14-20 08:00AM  
Feb-12-20 06:55AM  
Feb-10-20 04:08PM  
Feb-07-20 07:32AM  
Feb-06-20 08:00AM  
Jan-21-20 05:32AM  
Jan-19-20 09:13AM  
Jan-10-20 10:11AM  
Jan-09-20 04:05PM  
Dec-20-19 05:35PM  
Dec-05-19 08:00AM  
Dec-04-19 07:41AM  
Dec-03-19 04:01PM  
Dec-02-19 08:00AM  
Nov-25-19 08:00AM  
Nov-24-19 04:19PM  
Nov-15-19 04:29PM  
Nov-12-19 04:05PM  
Nov-06-19 04:05PM  
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rankin AubreyPresident, Innovation & TechFeb 01Sale25.9533,119859,438444,446Feb 03 08:13 PM
Rankin AubreyPresident, Innovation & TechDec 30Sale27.8233,119921,212477,565Jan 04 08:01 PM
Rankin AubreyPresident, Innovation & TechNov 30Sale23.8533,119789,888510,684Dec 02 08:55 PM
Rankin AubreyPresident, Innovation & TechOct 29Sale26.1533,119865,949543,803Oct 30 08:24 PM
Rankin AubreyPresident, Innovation & TechSep 28Sale26.1833,119867,055576,922Sep 30 09:21 PM